the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma - Trial NCT05834751
Access comprehensive clinical trial information for NCT05834751 through Pure Global AI's free database. This phase not specified trial is sponsored by Ou Bai, MD/PHD and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 144 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ou Bai, MD/PHD
The First Hospital of Jilin University
Timeline & Enrollment
N/A
May 01, 2023
Jul 01, 2025
Primary Outcome
Mobilization success rate
Summary
A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and
 safety of pegylated recombinant human granulocyte stimulating factor injection in the
 mobilization of autologous hematopoietic stem cells in lymphoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05834751
Non-Device Trial